Patient Advocacy in the Age of AI: An Industry Insider on Representation, Rigor, and the Future of Clinical Trials
Clinical trials generate the evidence that drives medical decisions, but who designs them, who runs them, and who is in them shapes everything about what that evidence can and cannot tell us. Join us for a fireside chat with a leader who has spent nearly two decades working to change that from the inside.
Racquel Racadio, DrPH, MPH leads Patient Advocacy at Amgen and founded the company's RISE team, one of the most recognized efforts in the biopharmaceutical industry for advancing diversity and representation in clinical research. From writing the foundational policy paper that launched RISE, to co-leading a global diversity initiative across competing pharmaceutical companies through TransCelerate, to championing the African American Heart Study, a 5,000-person cardiovascular observational study designed specifically to fill a critical evidence gap in Black populations, Racquel's career represents something rare: patient advocacy treated not as a communications function but as a scientific imperative that shapes how trials are designed before a single participant is ever enrolled.
If you are interested in clinical trial design, patient advocacy, health equity, drug development, or what it actually takes to change a large institution from the inside, this session is for you.
Dinner will be provided for the first 30 guests.
📍Edwards Building, Room 166 🕒 4:30pm–5:50pm
SPEAKER BIO
Racquel Racadio, DrPH, MPH Racquel Racadio is a patient advocacy, clinical research, and health equity expert with nearly two decades of experience advancing patient centricity and inclusive research in the biotechnology and pharmaceutical sectors. She currently leads Patient Advocacy for Amgen, a global biotechnology company, where she works to elevate the voices of patients, caregivers, and advocacy partners to shape solutions, address access barriers, and drive meaningful impact across both established and emerging therapeutic areas. With a background that also spans clinical development, medical affairs, and public health research focused on disparities in healthcare access and health outcomes. This led to Racquel founding Amgen's RISE (Representation in Clinical Research) Team, which is dedicated to improving the diversity and representation of participants in clinical trials and is considered an industry leader in these efforts. As such, Racquel is a thought leader on dismantling barriers to participation for communities historically excluded from clinical research.
This event is part of BIOS 297: Clinical Trials, Industry Perspectives. We are opening select sessions to the broader Stanford community. Seats are extremely limited, so please RSVP only if you are certain you can join.